Filtered By:
Management: Food and Drug Administration (FDA)
Procedure: Radiography
This page shows you your search results in order of date.
Order by Relevance | Date
Total 39 results found since Jan 2013.
Successful Treatment and Retreatment With Erdafitinib for a Patient With < em > FGFR3-TACC3 < /em > Fusion Squamous NSCLC: A Case Report
JTO Clin Res Rep. 2023 Mar 30;4(5):100511. doi: 10.1016/j.jtocrr.2023.100511. eCollection 2023 May.ABSTRACTFGFR3-TACC3 fusions have been identified in patients with multiple cancer types, and tumors with these alterations are potentially sensitive to selective FGFR inhibitors. However, there are no FGFR inhibitors approved by the U.S. Food and Drug Administration for the treatment of patients with NSCLC with FGFR alterations. Here, we report a case of a patient with FGFR3-TACC3 fusion squamous NSCLC who achieved a radiographic response and disease control for 11 months on initial treatment with erdafitinib and subsequently...
Source: Clinical Lung Cancer - May 22, 2023 Category: Cancer & Oncology Authors: Chi Pham Daenielle Lang Wade T Iams Source Type: research
TRK inhibitor in a patient with metastatic triple-negative breast cancer and < em > NTRK < /em > fusions identified < em > via < /em > cell-free DNA analysis
Ther Adv Med Oncol. 2023 Jan 30;15:17588359231152844. doi: 10.1177/17588359231152844. eCollection 2023.ABSTRACTTissue-agnostic indications for targeted therapies have expanded options for patients with advanced solid tumors. The Food and Drug Administration approvals of the programmed death-ligand 1 inhibitor pembrolizumab and the TRK inhibitors larotrectinib and entrectinib provide rationale for next-generation sequencing (NGS) in effectively all advanced solid tumor patients given potential for clinical responses even in otherwise refractory disease. As proof of concept, this case report describes a 64-year-old woman wit...
Source: Adv Data - February 6, 2023 Category: Epidemiology Authors: Arielle J Medford Lauren Oshry Baris Boyraz Lesli Kiedrowski Sofia Menshikova Anna Butusova Charles S Dai Tasos Gogakos Jennifer C Keenan Rachel H Occhiogrosso Phoebe Ryan Jochen K Lennerz Laura M Spring Beverly Moy Leif W Ellisen Aditya Bardia Source Type: research
Factors that guide selection among androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer
Clin Adv Hematol Oncol. 2022 May;20 Suppl 9(5):1-20.ABSTRACTProstate cancer is the most common cancer affecting men in the United States. A significant proportion of men have nonmetastatic castration-resistant prostate cancer (CRPC), in which biochemical progression is evidenced by rising levels of prostate-specific antigen without radiographic progression in the setting of castrate levels of testosterone. Historically, the preferred treatment for these patients has been observation and continued treatment with androgen deprivation therapy (ADT). The standard of care has recently evolved to include the addition of androgen...
Source: Clinical Prostate Cancer - May 17, 2022 Category: Cancer & Oncology Authors: Matthew B Rettig Himisha Beltran William K Oh Source Type: research
Poor Patient Follow-up After Metal-on-Metal Total Hip Arthroplasty
Orthopedics. 2022 Mar 4:1-5. doi: 10.3928/01477447-20220225-03. Online ahead of print.ABSTRACTRoutine follow-up approximately every 2 to 5 years after total hip arthroplasty (THA) is a common practice. However, although patients are informed of the importance of follow-up, our mean follow-up rate for patients after standard non-metal-on-metal (MOM) THA is only 19%. The US Food and Drug Administration has released several statements on the importance of follow-up every 2 years after MOM THA. With the potential risks of MOM THA apparently widely known, we report on our ability to obtain timely follow-up at 2 separate centers...
Source: Orthopedics - March 4, 2022 Category: Orthopaedics Authors: Timothy G Costales Patrick H Greenwell William Shield Danielle M Chapman William L Griffin David F Dalury Source Type: research
